Purpose: Programmed cell death protein-1 ligand (PD-L1) is an important prognostic predictor for immunotherapy of non-small cell lung cancer (NSCLC). This study aimed to develop a non-invasive deep learning and radiomics model based on positron emission tomography and computed tomography (PET/CT) to predict PD-L1 expression in NSCLC. Methods: A total of 136 patients with NSCLC between January 2021 and September 2022 were enrolled in this study. The patients were randomly divided into the training dataset and the validation dataset in a ratio of 7:3. Radiomics feature and deep learning feature were extracted from their PET/CT images. The Mann-whitney U-test, Least Absolute Shrinkage and Selection Operator algorithm and Spearman correlation a...
Purpose: Tumors are continuously evolving biological systems, and medical imaging is uniquely positi...
Aim: The development and evaluation of deep learning (DL) and radiomics based models for recurrence-...
Simple Summary The pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CCRT) i...
Background Currently, only a fraction of patients with non-small cell lung cancer (NSCLC) treated wi...
Background: We aimed to assess if quantitative radiomic features can predict programmed death ligan...
Different biomarkers based on genomics variants have been used to predict the response of patients t...
Purpose: The assessment of Programmed death-ligand 1 (PD-L1) expression has become a game changer in...
Purpose: We aimed to assess the ability of radiomics features extracted from baseline (PET/CT0) and ...
Different biomarkers based on genomics variants have been used to predict the response of patients t...
BackgroundThe expression level of the programmed cell death ligand 1 (PD-L1) appears to be a predict...
To assess if quantitative integrated deep learning and radiomics features can predict the PD-L1 expr...
BACKGROUND: Immunotherapies, such as programmed death 1/programmed death ligand 1 (PD-1/PD-L1) antib...
Background Identifying predictive non-invasive biomarkers of immunotherapy response is crucial to av...
Introduction In this study, we aim to build radiomics and multiomics models based on transcriptomics...
International audienceIn patients with non-small cell lung cancer (NSCLC) treated with immunotherapy...
Purpose: Tumors are continuously evolving biological systems, and medical imaging is uniquely positi...
Aim: The development and evaluation of deep learning (DL) and radiomics based models for recurrence-...
Simple Summary The pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CCRT) i...
Background Currently, only a fraction of patients with non-small cell lung cancer (NSCLC) treated wi...
Background: We aimed to assess if quantitative radiomic features can predict programmed death ligan...
Different biomarkers based on genomics variants have been used to predict the response of patients t...
Purpose: The assessment of Programmed death-ligand 1 (PD-L1) expression has become a game changer in...
Purpose: We aimed to assess the ability of radiomics features extracted from baseline (PET/CT0) and ...
Different biomarkers based on genomics variants have been used to predict the response of patients t...
BackgroundThe expression level of the programmed cell death ligand 1 (PD-L1) appears to be a predict...
To assess if quantitative integrated deep learning and radiomics features can predict the PD-L1 expr...
BACKGROUND: Immunotherapies, such as programmed death 1/programmed death ligand 1 (PD-1/PD-L1) antib...
Background Identifying predictive non-invasive biomarkers of immunotherapy response is crucial to av...
Introduction In this study, we aim to build radiomics and multiomics models based on transcriptomics...
International audienceIn patients with non-small cell lung cancer (NSCLC) treated with immunotherapy...
Purpose: Tumors are continuously evolving biological systems, and medical imaging is uniquely positi...
Aim: The development and evaluation of deep learning (DL) and radiomics based models for recurrence-...
Simple Summary The pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CCRT) i...